日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Impact of Semaglutide as Weight Management Medication on Clinical Parameters and Health-Related Quality of Life: A Single-Center Study from Saudi Arabia

司美格鲁肽作为体重管理药物对临床参数和健康相关生活质量的影响：一项来自沙特阿拉伯的单中心研究

期刊:Healthcare
影响因子:2.7
doi:10.3390/healthcare14070845
Dayel, Faten F Bin; Alanazi, Rakan J; Alenazi, Miteb A; Alkhalifah, Sahar; Dayel, Dalal F Bin; Mawkili, Wedad; Alwhaibi, Abdulrahman
发表日期：2026
文献求助 收藏

A Real-World Comparison of the Safety Profile for Immune Checkpoint Inhibitors in Oncology Patients

肿瘤患者免疫检查点抑制剂安全性特征的真实世界比较

期刊:Journal of Clinical Medicine
影响因子:2.9
doi:10.3390/jcm14020388
Alwhaibi, Abdulrahman; Alenazi, Miteb A; Alghadeer, Sultan; Mansy, Wael; Alsaif, Reem A; Abualreesh, Nawaf E; Alanazi, Rakan J; Alroumi, Abdullah; Alanazi, Saleh A
Checkpoint
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2025
文献求助 收藏

Evaluation of Pre-Treatment Assessment of Semaglutide Users: Balancing the Benefits of Weight Loss vs. Potential Health Consequences

对司美格鲁肽使用者治疗前评估的评价：平衡减重益处与潜在健康后果

期刊:Healthcare
影响因子:2.7
doi:10.3390/healthcare13151827
Bin Dayel, Faten F; Alanazi, Rakan J; Alenazi, Miteb A; Alkhalifah, Sahar; Alfaifi, Mohammed; Alghadeer, Sultan; Alwhaibi, Abdulrahman
发表日期：2025
文献求助 收藏

Medical and Financial Consequences of Using PCSK9 Inhibitors for Managing Hypercholesterolemia in Saudi Arabia: A Historical Cohort Study

在沙特阿拉伯使用PCSK9抑制剂治疗高胆固醇血症的医疗和经济后果：一项历史性队列研究

期刊:Healthcare
影响因子:2.7
doi:10.3390/healthcare13192428
AlRuthia, Yazed; Almutairi, Khlood Khaled; Aljammaz, Norah Abdulaziz; Alsuwayegh, Aseel; Alanazi, Miteb A; AlSulaiman, Rasha Fahad; Alfaori, Tareq Majed; Alabdan, Numan
PCSK9
CSK
代谢
发表日期：2025
文献求助 收藏

Real-World Comparison of Health-Related Quality of Life Associated with Use of Immune-Checkpoint Inhibitors in Oncology Patients

肿瘤患者使用免疫检查点抑制剂后健康相关生活质量的真实世界比较

期刊:Journal of Clinical Medicine
影响因子:2.9
doi:10.3390/jcm13164918
Alwhaibi, Abdulrahman; Alenazi, Miteb A; Alnofaie, Saad D; Aldekhail, Abdullah M; Alanazi, Rakan J; Alghadeer, Sultan; Alghamdi, Abdulrhman A; Alanazi, Saleh A
Checkpoint
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2024
文献求助 收藏

Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study

沙特阿拉伯类风湿性关节炎患者中托珠单抗与阿达木单抗联合依那西普的成本效益分析：一项单中心研究

期刊:
影响因子:
doi:10.1186/s12962-024-00522-7
Albahdal, Areej S; Alotaibi, Amjad M; Alanazi, Miteb A; Abanmy, Norah; Alwhaibi, Monira; AlRuthia, Yazed
关节炎
发表日期：2024
文献求助 收藏

Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi Arabia

利沙珠单抗和阿达木单抗治疗银屑病的疗效和成本效益比较：一项在沙特阿拉伯进行的真实世界研究

期刊:
影响因子:
doi:10.1186/s12962-023-00504-1
AlRuthia, Yazed; Alfakhri, Almaha H; Alharbi, Ibtisam; Alghamdi, Fadi Ali; Alanazi, Miteb A; Alrabiah, Abdullah Abdulrahman; Alsouan, Anwar Abdulrazzag; Alshaikh, Abdulrahman Abdullah; Almasaoud, Majed Ali
银屑病
发表日期：2023
文献求助 收藏

Drug-drug interactions and pharmacists' interventions among psychiatric patients in outpatient clinics of a teaching hospital in Saudi Arabia

沙特阿拉伯某教学医院门诊精神科患者的药物相互作用及药剂师干预

期刊:Saudi Pharmaceutical Journal
影响因子:3.4
doi:10.1016/j.jsps.2019.05.001
AlRuthia, Yazed; Alkofide, Hadeel; Alosaimi, Fahad Dakheel; Sales, Ibrahim; Alnasser, Albandari; Aldahash, Aliah; Almutairi, Lama; AlHusayni, Mohammed M; Alanazi, Miteb A
发表日期：2019
文献求助 收藏